{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-033894","form_type":"8-K","ticker":"VCEL","cik":"0000887359","company_name":"Vericel Corp","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.183200+00:00","generated_at":"2026-05-31T14:10:11.224539+00:00","sec_items":["9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vericel Q2 revenue rises 15% to $52.7M; MACI up 21%; raises FY2024 margin guidance to 71%","bullets":["MACI net revenue $44.1M (+21% YoY); NexoBrid revenue $0.8M (+76% QoQ); Burn Care franchise total $8.5M.","Gross margin 70% (up 430bps); adjusted EBITDA $6.3M (+42%), margin 12% (up 230bps).","FY2024 guidance reaffirmed: revenue $238-242M; gross margin raised to 71%, adjusted EBITDA margin to 21%.","MACI Arthro launch expected later Q3 2024; NexoBrid pediatric FDA approval anticipated in Q3 2024.","Net loss $4.7M ($0.10 diluted EPS) vs $5.0M loss in prior year; cash $154M, no debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-033894","json":"https://secwatch.observer/filing/0001628280-24-033894.json","markdown":"https://secwatch.observer/filing/0001628280-24-033894.md","text":"https://secwatch.observer/filing/0001628280-24-033894.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887359/000162828024033894/0001628280-24-033894-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887359/000162828024033894/vcel-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:10:11.224539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}